The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls

Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular (CV) risk markers. In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight.Carotid intima-media wall thickness (cIMT) was measured by B-mode ultrasonography, platelet...